Tags

Type your tag names separated by a space and hit enter

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.
Infect Genet Evol. 2020 09; 83:104327.IG

Abstract

Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year.

Authors+Show Affiliations

Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA; Zoology Department, Faculty of Science, Minia University, El-Minia 61519, Egypt. Electronic address: mohamedt1@uthscsa.edu.Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32320825

Citation

Abd El-Aziz, Tarek Mohamed, and James D. Stockand. "Recent Progress and Challenges in Drug Development Against COVID-19 Coronavirus (SARS-CoV-2) - an Update On the Status." Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases, vol. 83, 2020, p. 104327.
Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infect Genet Evol. 2020;83:104327.
Abd El-Aziz, T. M., & Stockand, J. D. (2020). Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases, 83, 104327. https://doi.org/10.1016/j.meegid.2020.104327
Abd El-Aziz TM, Stockand JD. Recent Progress and Challenges in Drug Development Against COVID-19 Coronavirus (SARS-CoV-2) - an Update On the Status. Infect Genet Evol. 2020;83:104327. PubMed PMID: 32320825.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. AU - Abd El-Aziz,Tarek Mohamed, AU - Stockand,James D, Y1 - 2020/04/19/ PY - 2020/04/05/received PY - 2020/04/15/revised PY - 2020/04/17/accepted PY - 2020/4/23/pubmed PY - 2020/6/26/medline PY - 2020/4/23/entrez KW - COVID-19 KW - Coronavirus KW - Pathogenesis KW - SARS-CoV-2 KW - Severe acute respiratory syndrome KW - Therapy KW - Vaccines SP - 104327 EP - 104327 JF - Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases JO - Infect Genet Evol VL - 83 N2 - Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year. SN - 1567-7257 UR - https://www.unboundmedicine.com/medline/citation/32320825/Recent_progress_and_challenges_in_drug_development_against_COVID_19_coronavirus__SARS_CoV_2____an_update_on_the_status_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-1348(20)30158-1 DB - PRIME DP - Unbound Medicine ER -